During the intraoperative management of patients with a history of chronic cannabis use, anesthesiologists are presented with unique considerations that necessitate careful planning and adjustment of anesthesia protocols. The interaction between cannabis and various anesthetic agents can significantly alter the anesthetic requirements, with chronic cannabis users often needing higher doses of induction agents, such as propofol. This increased demand is thought to result from cannabis compounds, particularly THC, modulating central nervous system receptors like GABA-A, thereby altering the patient's sensitivity to anesthetic agents. This complex interaction underscores the necessity for further research to better understand the impact of chronic cannabis use on anesthesia and to develop informed perioperative care guidelines.
The biphasic cardiovascular effects of cannabis, characterized by dose-dependent variations in heart rate and blood pressure, further complicate intraoperative management. Lower doses of cannabis can lead to sympathetic stimulation, resulting in tachycardia and slight hypertension, whereas higher doses may inhibit sympathetic activity, causing bradycardia and hypotension. These effects highlight the importance of continuous cardiovascular monitoring and the potential need for tailored interventions during surgery.
Additionally, numerous case reports have recently highlighted severe bleeding episodes associated with the recreational use of synthetic cannabinoids not approved by the FDA, such as K2 or Spice, prompting health alerts across the nation. Patients exhibited continuous, unexplained bleeding, accompanied by significantly high prothrombin time and international normalized ratio values. Despite treatments with intravenous vitamin K and fresh frozen plasma, the bleeding continued. It is suspected that this phenomenon may result from an interaction between synthetic cannabinoids and warfarin, although there was no documented exposure to anticoagulants or rodenticides in these instances.
Pain management during and after surgery also poses a challenge, as cannabis users may report higher pain scores and exhibit increased sensitivity to pain. This phenomenon suggests that traditional analgesic dosing may be insufficient for this patient group, pointing to the potential benefits of a multimodal analgesic approach. Incorporating a combination of acetaminophen, nonsteroidal anti-inflammatory drugs, or cyclooxygenase-2-specific inhibitors, along with local or regional analgesia techniques when feasible, could enhance pain control and improve patient comfort.
Given the variability in response to both anesthetic and analgesic agents among cannabis users, anesthesiologists must remain adaptable and vigilant, ready to adjust dosing as needed to ensure optimal anesthesia depth and pain management. The reliance on tools like the bispectral index (BIS) for monitoring anesthesia depth may also be affected, as cannabis-induced changes in EEG activity could impact the reliability of BIS readings. This complexity necessitates a cautious approach, emphasizing the need for ongoing research and the development of evidence-based practices tailored to the needs of patients with a history of cannabis use.
| Issue | Anesthetic implication |
|---|---|
| Induction dosing | Chronic users often require higher doses of induction agents such as propofol, thought to reflect THC modulation of CNS receptors including GABAA |
| Cardiovascular response | Biphasic and dose-dependent: lower doses produce sympathetic stimulation with tachycardia and slight hypertension, higher doses inhibit sympathetic activity causing bradycardia and hypotension |
| Monitoring | Continuous cardiovascular monitoring; bispectral index readings may be less reliable because cannabis alters EEG activity |
| Bleeding | Severe unexplained bleeding with markedly elevated prothrombin time and INR reported after synthetic cannabinoids such as K2 or Spice, persisting despite intravenous vitamin K and fresh frozen plasma |
| Pain management | Users may report higher pain scores and increased pain sensitivity; consider multimodal analgesia with acetaminophen, NSAIDs or COX-2-specific inhibitors, plus local or regional techniques where feasible |
